Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Glaxo CEO’s Bonus Reduced by China Bribery Investigation

Don't Miss Out —
Follow us on:

Feb. 27 (Bloomberg) -- GlaxoSmithKline Plc Chief Executive Officer Andrew Witty received a bonus less than the maximum possible because of a Chinese investigation into bribery allegations against the company.

Witty’s bonus of 1.88 million pounds ($3.13 million) was lower than the potential 2.12 million pounds he might have gotten, Glaxo said today in its annual report. Even so, the bonus was more than double the amount awarded for 2012 after the company won regulatory approval of six products last year.

China began an anti-corruption probe focused on London-based Glaxo in July. Allegations by China’s government that Glaxo bribed hospitals, doctors and officials contributed to a plunge in revenue from that country and a hit to its corporate image.

“Both Sir Andrew and the board are mindful of the impact this issue has had on the reputation of the company,” Tom de Swaan, chairman of the board’s remuneration committee, said in a statement in the report. “As a result, the bonuses awarded for 2013 were lower than they otherwise might have been.”

Earlier this month, Glaxo forecast revenue will rise by about 2 percent this year as the company introduces the newly approved medicines.

“Andrew Witty’s bonus reflects GSK’s very strong performance in 2013, which included receiving the highest number of product approvals of any company, meeting the top end of our financial guidance and delivering the best total shareholder return since the formation of the company with more than 5 billion pounds returned to shareholders,” Glaxo spokesman Simon Steel said in an e-mail.

To contact the reporter on this story: Makiko Kitamura in London at mkitamura1@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.